Anavex Life Sciences Corp (NASDAQ:AVXL) Expected to Post Earnings of -$0.15 Per Share

Equities research analysts expect Anavex Life Sciences Corp (NASDAQ:AVXL) to post ($0.15) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences posted earnings per share of ($0.13) in the same quarter last year, which would indicate a negative year over year growth rate of 15.4%. The business is scheduled to issue its next quarterly earnings report on Wednesday, December 11th.

On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.63) to ($0.62). For the next financial year, analysts forecast that the company will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.64) to ($0.62). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Anavex Life Sciences.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03.

AVXL has been the subject of several recent research reports. Dawson James initiated coverage on Anavex Life Sciences in a research report on Wednesday, July 24th. They set a “buy” rating and a $16.00 price objective for the company. Zacks Investment Research lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Janney Montgomery Scott initiated coverage on Anavex Life Sciences in a research report on Tuesday, June 18th. They set a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $9.46.

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of Anavex Life Sciences during the second quarter valued at $38,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Anavex Life Sciences by 562.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 105,179 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 89,305 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Anavex Life Sciences by 1,023.0% during the second quarter. Jane Street Group LLC now owns 142,349 shares of the biotechnology company’s stock valued at $480,000 after acquiring an additional 129,673 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Anavex Life Sciences by 145.2% during the second quarter. Vanguard Group Inc. now owns 1,990,674 shares of the biotechnology company’s stock valued at $6,708,000 after acquiring an additional 1,178,831 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Anavex Life Sciences by 1,145.6% during the second quarter. BlackRock Inc. now owns 2,812,421 shares of the biotechnology company’s stock valued at $9,477,000 after acquiring an additional 2,586,635 shares in the last quarter. Hedge funds and other institutional investors own 22.34% of the company’s stock.

Shares of Anavex Life Sciences stock opened at $2.77 on Wednesday. The business has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $3.00. Anavex Life Sciences has a 12 month low of $1.25 and a 12 month high of $4.09.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Featured Story: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Anavex Life Sciences (AVXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit